Comparisons
- CJC-1295 vs Ipamorelin (2026): Evidence & Regulatory Status Compared
CJC-1295 vs Ipamorelin: two research growth-hormone peptides often stacked. Evidence, FDA status and how they differ, side by side.
- GHK-Cu vs BPC-157 (2026): Evidence & Regulatory Status Compared
GHK-Cu vs BPC-157: a cosmetic copper peptide versus a research repair peptide. Evidence, FDA status and uses, side by side.
- Tesamorelin vs CJC-1295 (2026): Evidence & Regulatory Status Compared
Tesamorelin vs CJC-1295: an FDA-approved GHRH analog versus a research peptide. Evidence, approval and status, side by side.
- Epitalon vs DSIP (2026): Evidence & Legal Status Compared
Epitalon vs DSIP: two research peptides both up for the July 2026 FDA vote on insomnia, with different biology and the same preclinical evidence.
- Epitalon vs MOTS-c (2026): Evidence & Legal Status Compared
Epitalon vs MOTS-c: two research peptides marketed for longevity, with very different biology and the same July 2026 FDA compounding meeting.
- Epitalon vs Semax (2026): Evidence & Legal Status Compared
Epitalon vs Semax: two research peptides from the same Russian lineage, stacked for anti-ageing and cognition, with the same July 2026 FDA review.
- Semax vs DSIP (2026): Evidence & Legal Status Compared
Semax vs DSIP: two research neuropeptides with different targets — cognition versus sleep — and the same July 2026 FDA compounding vote.
- TB-500 vs KPV (2026): Evidence & Legal Status Compared
TB-500 vs KPV: research peptides for wound healing and inflammation, both facing the same July 2026 FDA compounding vote, side by side.
- BPC-157 vs KPV (2026): Evidence & Legal Status Compared
BPC-157 vs KPV: both are research peptides for healing and inflammation, facing the same July 2026 FDA compounding vote. Evidence and status, side by side.
- BPC-157 vs TB-500 (2026): Evidence & Legal Status Compared
BPC-157 vs TB-500: research peptides for healing, both facing the same July 2026 FDA compounding vote. Evidence and regulations, side by side.